Krugman S
Dev Biol Stand. 1975;30:363-7.
Studies conducted in 1970 and 1971 with heat-inactivated MS-2 serum revealed that this active immunizing procedure was associated with a protective effect, a more attenuated hepatitis B infection and a decreased hepatitis B carrier rate. More recent studies have revealed striking differences in the response of unimmunized and immunized persons following a parenteral exposure to the MS-2 strain of hepatitis B virus. Serial tests for the detection of hepatitis B surface antigen (HBsAg), DNA polymerase activity, serum transaminase (SGOT), antibody to HBsAg (anti-HBs) and antibody to hepatitis B core antigen (anti-HBc) revealed the following findings. In serosusceptible unimmunized persons HBsAg was detectable about 4 weeks after exposure, DNA polymerase activity at about 6 weeks, abnormal SGOT levels at about 8 weeks, anti-HBc at about 8-10 weeks, and anti-HBs usually after 20 weeks. In successfully immunized persons HBsAg, DNA polymerase activity, abnormal SGOT levels, and anti-HBc were not detectable, evidence of a booster response of pre-existing or non-detectable anti-HBs was observed one to two weeks after exposure. Studies by various investigators have revealed that anti-HBs is associated with protection and resistance to reinfection. In contrast, anti-HBc is not protective and does not correlate positively with either resistance to infection or recovery from infection. The availability of sophisticated biophysical and biochemical techniques has enabled several investigators to prepare candidate inactivated hepatitis B vaccines from purified preparations of HBsAg. The successful propagation of hapatitis B virus infection to susceptible chimpanzees has provided an excellent animal model for the evaluation of hepatitis B vaccines. At the present time various investigators are studying the immunogenic and protective effect of the vaccine in these animals. Prospects for the development of a vaccine for the prevention of viral hepatitis type B are encouraging. It is extraordinary that this objective will be achieved in spite of the failure to isolate the etiologic agent in tissue culture.
1970年和1971年对热灭活MS - 2血清进行的研究表明,这种主动免疫程序具有保护作用,能使乙型肝炎感染更趋缓和,并降低乙肝携带者率。最近的研究显示,未免疫者和免疫者在经肠道外接触乙肝病毒MS - 2株后的反应存在显著差异。对乙肝表面抗原(HBsAg)、DNA聚合酶活性、血清转氨酶(SGOT)、抗HBsAg抗体(抗 - HBs)和抗乙肝核心抗原抗体(抗 - HBc)进行的系列检测揭示了以下结果。在血清易感的未免疫者中,接触后约4周可检测到HBsAg,约6周可检测到DNA聚合酶活性,约8周SGOT水平异常,约8 - 10周可检测到抗 - HBc,抗 - HBs通常在20周后出现。在成功免疫者中,未检测到HBsAg、DNA聚合酶活性、SGOT水平异常及抗 - HBc,接触后1至2周观察到存在的或原本未检测到的抗 - HBs出现增强反应的证据。不同研究者的研究表明,抗 - HBs与保护作用及抵抗再感染有关。相比之下,抗 - HBc没有保护作用,与抗感染能力或感染恢复情况均无正相关。先进的生物物理和生化技术的应用使一些研究者能够从纯化的HBsAg制剂中制备候选灭活乙肝疫苗。乙肝病毒感染在易感黑猩猩中的成功传播为评估乙肝疫苗提供了优良的动物模型。目前,不同研究者正在研究该疫苗在这些动物中的免疫原性和保护作用。开发预防乙型病毒性肝炎疫苗的前景令人鼓舞。尽管未能在组织培养中分离出病原体,但实现这一目标仍是非同寻常的。